意大利索林集团Sorin Group 
一家意大利致力于医疗技术领域的跨国公司，它最近宣布将推出一种在其种类中堪称革命性的人工心脏瓣膜。一种能不打开胸部或停止心脏而被植入患者的产品。所以简而言之，或许不必实施外科缝合术。这是一种生物学支持结构的瓣膜，由于它利用了其它的医疗技术大约有十年，其基本概念已经得到完善并经过试验。很长的孵化期使之能科学地展示其可靠性，现在对之已经不再有疑义了。

Sorin Group is a global company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.
The Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.